Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest® 50 or Systen® (Evorel®) 50

Maturitas

Volumn 27, Issue 2, 1997, Pages 179-186

  Reginster, J Y ^a   Albert, A ^a   Deroisy, R ^a   Colette, J ^a   Vrijens, B ^a   Blacker, C ^b   Brion, N ^c   Caulin, F ^d   Mayolle, C ^c   Regnard, A ^e   Scholler, R ^b   Franchimont, P ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b FRH   (France)

^c Versus   (France)

^d RPR   (France)

^e Theraplix   (France)

Author keywords

Estradiol; Hormone replacement therapy; Pharmacokinetics; Post menopause; Transdermal administration

Indexed keywords

ESTRADIOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADULT; BIOLOGICAL AVAILABILITY; COHORT STUDIES; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RADIOIMMUNOASSAY; TIME FACTORS;

EID: 8544247156     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00027-3     Document Type: Article

References (39)

1. Whittington R, Faulds D. Hormone replacement therapy I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. PharmacoEconomics 1994; 5: 419-445.
2. Jacobs S, Hillard TC. Hormone replacement therapy in the aged. A state of the art review. Drugs Aging 1996; 8: 193-213.
3. Boyd ME. The risks and benefits of hormone replacement therapy. CJS 1995; 38: 415-419.
4. Shibata HR. Hormone replacement therapy: boon or bane? CJS 1995; 38: 409-414.
5. Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pharmacol 1995; 49: 87-90.
6. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995; 85: 6-10.
7. National Opinion Poll. The menopause revolution. London: Ciba Geigy, 1992.
8. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332-1334.
9. Pedersen SH, Jeune B. Prevalence of hormone replacement therapy in a sample of middle-aged women. Maturitas 1988; 9: 339-345.
10. Cheang A, R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Safety 1993; 9: 365-379.
11. Dupont WD, Page DL. Menopausal oestrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72.
12. Steinberg KK, Thacker SB, Smith SJ et al. A meta-analysis of the effects of oestrogen replacement therapy and the risk of breast cancer. J Am Med Assoc 1991; 265: 1985-1990.
13. Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle aged women. J Am Med Assoc 1995; 274: 137-142.
14. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1593.
15. AFNOR. Détermination de la répétabilité et de la reproducibilité d'une méthode d'essai normalisée par essais interlaboratoires. NF ISO 5725.
16. Currie LA. Limits for qualitative detection and quantitative determination. Application to radiochemistry. Anal Chem 1968; 40: 568-593.
17. Scoller R. Exactitude. Fidélité. Limite de détection. In: Contrôle de qualité en hormonologie. I. Stéroïdes urinaires. Paris: Editions SEPE, 1977, 31-78.
18. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8: 7-20.
19. Zerbe GO. Randomization analysis of randomized blocks design extended to growth and response curves. Commun Stat 1979; A8: 191-205.
20. Scott RT, Ross B, Anderson C, Archer D. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991; 77: 758-764.
21. Van Leusden HAIM, Albertyn G, Verlaine C, Van Ruymbeke J. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Int J Fertil 1993; 38: 210-218.
22. Guichard J-P, Sauron R, Dutertre J-P et al. A pilot study of the comparative bioavailability of estradiol from two different estradiol transdermal systems: Oesclim® 50 and Systen® 50. Curr Ther Res 1995; 56: 1022-1032.
23. Studd JWW, McCarthy K, Zamblera D et al. Efficacy and tolerance of Menorest® compared to Premarin® in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 1995; 22: 105-114.
24. Fotherby K. Variability of pharmacokinetic parameters for contraceptive steroids. J Steroid Biochem 1983; 19: 817-820.
25. Anderson F. Kinetics and pharmacology of estrogens in pre- and postmenopausal women. J Steroid Biochem 1983; 19: 20.
26. Powers MS, Schenkel L, Darley PE et al. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-1106.
27. Reginster JY, Christiansen C, Dequinze B et al. Effect of transdermal 17β-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcif Tissue Int 1993; 53: 13-16.
28. Ribot C, Tremollieres F, Pouilles M et al. Preventive effects of transdermal 17β-estradiol on postmenopausal bone loss: a 2-year prospective study. Obstet Gynecol 1990; 75 (Suppl): 42S-43S.
29. Stevenson JC, Cust MP, Gangar KF et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 335: 265-269.
30. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium. Ann Intern Med 1987; 106: 40-45.
31. Studd JWW, Holland EFN, Leather AT, Smith RNJ. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994; 101: 787-791.
32. Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int J Fertil 1993; 38: 79-91.
33. Nichols KC, Schenkel L, Benson H. 17β-Estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Survey 1984; 39: 230-245.
34. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Br Med J 1987; 295: 915.
35. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90: 107-110.
36. Field CS, Ory SJ, Wahner HW et al. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168: 114-121.
37. Hillard TC, Whitcroft SJ, Marsh MS et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 1994; 4; 341-348.
38. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63.
39. Craig A, Guilford S. Endocrine assessment of the climacteric period in selecting patients clinical trials. Br J Clin Res 1993; 4: 1-9.